Delivery Order 36F79719D0024-36C24521F0435

Horizon Therapeutics USA Inc. was awarded a $99,352.32 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5. The firm fixed price order is for the drug KRYSTEXXA 8MG and has an anticipated completion date of April 25, 2022. Performance will take place in La Vergne, Tennessee. No set-aside designation was applied to this order under the GSA Schedule contract...

Horizon Therapeutics USA Inc. was awarded a $165,587.20 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5. The firm fixed price order is for the drug KRYSTEXXA 8MG and has a period of performance through June 23, 2022 at the place of performance in La Vergne, Tennessee. No set-aside designation was used for this order placed under GSA Schedule contract number...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a $105,097.84 delivery order to Horizon Therapeutics USA Inc. against the Pharmaceuticals and Drugs Federal Supply Schedule contract. The order is for the drug KRYSTEXXA 8MG and will be fulfilled by the vendor's place of performance in La Vergne, Tennessee by October 16, 2020. No set-aside designation was used for this firm fixed price order to support the VA's healthcare programs.

Horizon Therapeutics USA Inc. was awarded a $65,686.15 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 2. The firm fixed price order is for the delivery of KRYSTEXXA 8GM/ML VIAL to a location in Lake Forest, Illinois, with an anticipated completion date of October 23, 2020. The order was placed under GSA Schedule contract FSS-61-IB and does not contain any set...

Horizon Therapeutics USA Inc. was awarded a $59,142.04 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5. The firm fixed price order is for the delivery of KRYSTEXXA 8MG to the place of performance in La Vergne, Tennessee, with an anticipated completion date of April 15, 2021. The contract was awarded on April 14, 2021 under the GSA Schedule master contract for...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a $59,142.04 delivery order to Horizon Therapeutics USA Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The delivery order is for the drug KRYSTEXXA 8MG, with a completion date of November 3, 2021. The contract was awarded on November 2, 2021 and utilizes a firm fixed price pricing structure. Performance will take place in La Vergne, Tennessee. No set-aside...

This federal contract award is for the delivery of the pharmaceutical product KRYSTEXXA 8MG to the Department of Veterans Affairs (VA) Veterans Health Administration. The $2,425.46 firm-fixed price delivery order was awarded to the prime contractor Vifor (International) AG, a global biotechnology company that provides pharmaceuticals and drugs through its Federal Supply Schedule contract. The contract is associated with the VA's Pharmaceuticals and Drugs (FSS-61-IB) Schedule, and the delivery...

The U.S. Department of Veterans Affairs (VA) awarded a $76,896.72 firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The award is part of Horizon's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and is placed by the VA's Veterans Integrated Service Network (VISN) 5. This delivery order supports the VA's mission to provide comprehensive healthcare services to the veteran population, as KRYSTEXXA is...

The Department of Veterans Affairs Veterans Health Administration (VHA) awarded a delivery order to Horizon Therapeutics USA Inc. for KRYSTEXXA 8MG, a specialty pharmaceutical product. The order, valued at $55,903.32, was placed against Horizon Therapeutics' Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) and did not have a set-aside designation. Horizon Therapeutics is a global biotechnology company that provides orphan drugs and specialty pharmaceuticals to support...

This delivery order for $55,903.32 was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 to Horizon Therapeutics USA Inc. against the company's Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The firm fixed price order, with no set-aside designation, is for the medication KRYSTEXXA 8MG and aims to supply VHA hospitals and clinics in La Vergne, Tennessee with this orphan disease treatment through...